2002
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS, Hong WK. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Seminars In Oncology 2002, 29: 18-30. PMID: 12422310, DOI: 10.1053/sonc.2002.35644.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaEpidermal growth factor receptorIMC-C225Cell carcinomaAnti-epidermal growth factor receptor monoclonal antibodyLow patient survival rateRefractory squamous cell carcinomaLocoregional disease recurrencePromising response ratesImportant adverse eventsPatient survival ratesPhase I studiesReceptor monoclonal antibodyTreatment of headHuman tumor xenograftsExtracellular receptor sitesEnhanced tumor invasivenessInhibition of metastasisInhibition of angiogenesisAnticancer treatment strategiesGrowth factor receptorIMC-225Cancer cell linesAdverse eventsPotent antitumor activityMonoclonal antibodies to target epidermal growth factor receptor–positive tumors
Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor–positive tumors. Cancer 2002, 94: 1593-1611. PMID: 11920518, DOI: 10.1002/cncr.10372.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorAnti-EGFR monoclonal antibodiesMonoclonal antibodiesHuman tumorsEnglish-language literature searchEpidermal growth factor receptor (EGFR) positive tumorsMonoclonal antibody therapyReceptor-positive tumorsEGFR monoclonal antibodyDevelopment of malignancyGrowth of tumorsABX-EGFGrowth factor receptorIMC-C225Overall survivalAntibody therapyTraditional cytotoxicsCommon malignancyPoor prognosisClinical trialsEpithelial tumorsVivo effectsTumor managementUnmet needEMD 55900Targeted Therapy Using Novel Agents in the Treatment of Non—Small-Cell Lung Cancer
Herbst RS. Targeted Therapy Using Novel Agents in the Treatment of Non—Small-Cell Lung Cancer. Clinical Lung Cancer 2002, 3: s30-s38. PMID: 14720353, DOI: 10.3816/clc.2002.s.006.Peer-Reviewed Original ResearchCell lung cancerVascular endothelial growth factorProtein kinase C inhibitorLung cancerKinase C inhibitorSpecific cellular mechanismsCell cycle inhibitionEGFR tyrosine kinaseSignal transductionTyrosine kinaseKey enzymeReceptor-targeted therapyTreatment of NSCLCTumor growth delayC inhibitorEndothelial growth factorCellular mechanismsOSI-774IMC-C225Advanced NSCLCPoor prognosisMajor classesTargeted therapyNovel agentsTherapeutic improvementEpidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancers
Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Seminars In Oncology 2002, 29: 27-36. PMID: 11894011, DOI: 10.1053/sonc.2002.31525.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellCetuximabCombined Modality TherapyErbB ReceptorsGene Expression Regulation, NeoplasticHalf-LifeHead and Neck NeoplasmsHumansNeoplasm MetastasisNeoplasm Recurrence, LocalRadiation-Sensitizing AgentsRandomized Controlled Trials as TopicSalvage TherapyConceptsSquamous cell carcinomaEpidermal growth factor receptorIMC-C225Phase II trialGrowth factor receptorCell carcinomaII trialFactor receptorRadiation therapyNon-small cell lung cancer xenograftsNon-small cell lung cancerGemcitabine/carboplatin combinationSeparate phase II trialsAdvanced squamous cell carcinomaCell lung cancer xenograftsOngoing phase II trialEastern Cooperative Oncology GroupPhase III registration trialPhase I pharmacokinetic studyCultured human squamous cell carcinomasHuman squamous cell carcinomaPaclitaxel/carboplatinSecond-line settingStandard salvage regimensTreatment-naive patientsIMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer
Herbst R, Hong W. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Seminars In Oncology 2002, 29: 18-30. DOI: 10.1016/s0093-7754(02)70087-0.Peer-Reviewed Original ResearchSquamous cell carcinomaEpidermal growth factor receptorIMC-C225Cell carcinomaAnti-epidermal growth factor receptor monoclonal antibodyLow patient survival rateRefractory squamous cell carcinomaLocoregional disease recurrencePromising response ratesImportant adverse eventsPatient survival ratesPhase I studiesReceptor monoclonal antibodyTreatment of headHuman tumor xenograftsExtracellular receptor sitesEnhanced tumor invasivenessInhibition of metastasisInhibition of angiogenesisAnticancer treatment strategiesGrowth factor receptorIMC-225Cancer cell linesAdverse eventsPotent antitumor activity
2001
Epidermal growth factor receptor biology (IMC-C225)
Kim E, Khuri F, Herbst R. Epidermal growth factor receptor biology (IMC-C225). Current Opinion In Oncology 2001, 13: 506-513. PMID: 11673692, DOI: 10.1097/00001622-200111000-00014.Peer-Reviewed Original ResearchConceptsIMC-C225Epidermal growth factor receptor biologyMonoclonal antibodiesLigand-linked toxinsOverall clinical outcomeOverall poor prognosisTyrosine kinase inhibitorsTyrosine kinase inhibitionOverexpression of EGFRNovel monoclonal antibodyClinical outcomesPoor prognosisTreatment of cancerRadiation therapySolid tumorsEpithelial cancersTumor proliferationEGFRGrowth factorKinase inhibitorsCancerReceptor biologyAntibodiesKinase inhibitionEGF receptorIMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer
Herbst R, Kim E, Harari P. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opinion On Biological Therapy 2001, 1: 719-732. PMID: 11727507, DOI: 10.1517/14712598.1.4.719.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaEpidermal growth factor receptorIMC-C225Anti-epidermal growth factor receptor monoclonal antibodyAnti-EGFR monoclonal antibodiesMonoclonal antibodiesLocoregional disease recurrenceImportant adverse eventsPhase I studiesReceptor monoclonal antibodyExcellent response ratesTreatment of headHuman tumor xenograftsExtracellular receptor sitesInhibition of metastasisEnhanced tumor invasionPotent antitumour activityAnticancer treatment strategiesGrowth factor receptorCancer cell linesAdverse eventsRefractory diseaseSkin rashWeekly infusionsDisease recurrence